[go: up one dir, main page]

MX383561B - Composiciones y kits para usarse en el tratamiento de un sujeto con síntomas de accidente cerebrovascular o infarto agudo de miocardio (iam). - Google Patents

Composiciones y kits para usarse en el tratamiento de un sujeto con síntomas de accidente cerebrovascular o infarto agudo de miocardio (iam).

Info

Publication number
MX383561B
MX383561B MX2017005793A MX2017005793A MX383561B MX 383561 B MX383561 B MX 383561B MX 2017005793 A MX2017005793 A MX 2017005793A MX 2017005793 A MX2017005793 A MX 2017005793A MX 383561 B MX383561 B MX 383561B
Authority
MX
Mexico
Prior art keywords
ami
kits
compositions
myocardial infarction
symptoms
Prior art date
Application number
MX2017005793A
Other languages
English (en)
Other versions
MX2017005793A (es
Inventor
Victor Gurewich
Original Assignee
Thrombolytic Science Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrombolytic Science Llc filed Critical Thrombolytic Science Llc
Publication of MX2017005793A publication Critical patent/MX2017005793A/es
Publication of MX383561B publication Critical patent/MX383561B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención se refiere a una composición para usar en el tratamiento de un sujeto con síntomas de un accidente cerebrovascular o infarto de miocardio aguado (AMI) a una velocidad máxima de lisis de coágulos y con efectos secundarios hemorrágicos asociados mínimos, la composición comprende: una primera composición que comprende menos de 5 mg del activador de plasminógeno en tejidos (t PA), en donde la primera composición se prepara o se administrará a un sujeto en un régimen de dosificación de un bolo que comprende de 2 a 4.5 mg de t PA; y una segunda composición que comprende un mutante de pro-uroquinasa (mproUK), comprende una sustitución de lisina por histidina en la posición de aminoácidos 300 (Lys300 His) de pro-uroquinasa, en donde la segunda composición se prepara para que se administre a un sujeto mediante una infusión intravenosa en un régimen de dosificación de 60 a 120 mg/hora durante 60 a 90 minutos después de la administración de la primera composición; en donde el sujeto se identifica para que haya tenido potencialmente un accidente cerebrovascular o AMI sin determinar la causa del accidente cerebrovascular antes dela administración la primer composición; y en donde se alcanza una velocidad máxima de lisis de coágulos con efectos secundarios hemorrágicos asociados mínimos. Una composición que contiene a la molécula de enlace y su uso médico.
MX2017005793A 2014-11-03 2015-11-03 Composiciones y kits para usarse en el tratamiento de un sujeto con síntomas de accidente cerebrovascular o infarto agudo de miocardio (iam). MX383561B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462074374P 2014-11-03 2014-11-03
PCT/US2015/058878 WO2016073514A2 (en) 2014-11-03 2015-11-03 Methods and compositions for safe and effective thrombolysis

Publications (2)

Publication Number Publication Date
MX2017005793A MX2017005793A (es) 2017-10-23
MX383561B true MX383561B (es) 2025-03-14

Family

ID=55910021

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005793A MX383561B (es) 2014-11-03 2015-11-03 Composiciones y kits para usarse en el tratamiento de un sujeto con síntomas de accidente cerebrovascular o infarto agudo de miocardio (iam).

Country Status (10)

Country Link
US (2) US11213574B2 (es)
EP (2) EP3215221B1 (es)
JP (1) JP6826040B2 (es)
CN (1) CN107073292B (es)
CA (1) CA2966332C (es)
DK (1) DK3215221T3 (es)
EA (1) EA035358B1 (es)
ES (1) ES2788697T3 (es)
MX (1) MX383561B (es)
WO (1) WO2016073514A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3215221T3 (da) 2014-11-03 2020-05-11 Thrombolytic Science Llc Fremgangsmåder og sammensætninger til sikker og effektiv trombolyse
WO2018232305A1 (en) * 2017-06-16 2018-12-20 Thrombolytic Science, Llc Methods and compositions for thrombolysis
CN107516010B (zh) * 2017-08-19 2021-02-09 上海矩点医疗科技有限公司 溶栓剂量模型的构建方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381346A (en) 1979-11-13 1983-04-26 Huasin Syed S Isolation of plasminogen activators useful as therapeutic and diagnostic agents
GB8623823D0 (en) 1986-10-03 1986-11-05 Sandoz Ltd Therapeutic lysis of fibrin blood clots
GB2197195B (en) 1986-10-03 1991-01-23 Sandoz Ltd Improvments in or relating to organic compounds
US5108901A (en) 1988-09-02 1992-04-28 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
GB8823833D0 (en) 1988-10-11 1988-11-16 Erba Carlo Spa Production of human prourokinase
US5843089A (en) 1990-12-28 1998-12-01 Boston Scientific Corporation Stent lining
US5674192A (en) 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
ES2107041T3 (es) * 1992-06-03 1997-11-16 Genentech Inc Variantes de activador de plasminogeno tisular obtenidos por glicosilacion, que presentan propiedades terapeuticas.
WO1994018315A1 (en) 1993-02-05 1994-08-18 Vascular Laboratories, Inc. Use of intra-platelet urokinase-type plasminogen activators for long-term inhibition of thrombosis
US5472692A (en) 1993-07-02 1995-12-05 New England Deaconess Hospital Corporation Pro-urokinase mutants
US5510330A (en) 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
US5810767A (en) 1994-05-11 1998-09-22 Localmed, Inc. Method and apparatus for pressurized intraluminal drug delivery
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5569197A (en) 1994-12-21 1996-10-29 Schneider (Usa) Inc Drug delivery guidewire
CN1088893C (zh) 1994-12-29 2002-08-07 索尼公司 磁盘盒
US6759042B2 (en) 1999-06-04 2004-07-06 Thrombotech Ltd Use of cross-linked, covalently bound urokinase plasminogen activator (scuPA)-urokinase plasminogen activator receptor (suPAR) complex as a fibrinolytic agent
US6867177B2 (en) 1999-08-13 2005-03-15 The Trustees Of Columbia University In The City Of New York CD39/ECTO-adpase as a treatment for thrombotic and ischemic disorders
US6699230B2 (en) 2000-05-10 2004-03-02 Minnesota Medical Physics, Llc Apparatus and method for out-of-hospital thrombolytic therapy
GB0025473D0 (en) 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
CN1142278C (zh) 2001-04-04 2004-03-17 刘建宁 一类能被尿激酶或自身激活的尿激酶原变体及其编码基因、制备方法和用途
US7084118B2 (en) 2002-02-22 2006-08-01 Genentech, Inc. Combination treatment with t-PA variant and low molecular weight heparin
US7070958B2 (en) 2003-04-18 2006-07-04 Thrombolytic Science, Inc. Methods of making pro-urokinase mutants
CA2426115A1 (en) 2003-04-18 2004-10-18 Victor Gurewich Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots
JP2006241109A (ja) 2005-03-04 2006-09-14 Paion Deutschland Gmbh ヒトＰセレクチンおよびＤＳＰＡα１に対する抗体を含む融合タンパク質
PL2380587T3 (pl) * 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu
US7837992B2 (en) 2006-06-22 2010-11-23 Beth Israel Deaconess Medical Center C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
US20070298024A1 (en) * 2006-06-22 2007-12-27 Thrombolytic Science, Inc. C-1 inactivator inhibits two-chain urokinase mutant and limits hemostatic bleeding during thrombolysis
US20090010916A1 (en) * 2006-06-22 2009-01-08 Victor Gurewich C-1 Inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
CN101015686B (zh) * 2007-02-06 2010-05-19 中国人民解放军军事医学科学院基础医学研究所 一种溶栓药物增效剂及其制备方法
CN101549150A (zh) * 2008-03-31 2009-10-07 刘建宁 尿激酶原及尿激酶原变体在急性心肌梗塞易化经皮冠状动脉介入中的应用
DK3215221T3 (da) 2014-11-03 2020-05-11 Thrombolytic Science Llc Fremgangsmåder og sammensætninger til sikker og effektiv trombolyse

Also Published As

Publication number Publication date
US11213574B2 (en) 2022-01-04
US20180311322A1 (en) 2018-11-01
CN107073292A (zh) 2017-08-18
EP3708226A1 (en) 2020-09-16
EP3215221A2 (en) 2017-09-13
EA035358B1 (ru) 2020-06-01
EP3215221A4 (en) 2018-08-08
EP3215221B1 (en) 2020-02-26
CN107073292B (zh) 2021-07-02
WO2016073514A3 (en) 2016-08-11
JP2017533961A (ja) 2017-11-16
JP6826040B2 (ja) 2021-02-03
WO2016073514A2 (en) 2016-05-12
BR112017008749A2 (pt) 2017-12-19
CA2966332A1 (en) 2016-05-12
MX2017005793A (es) 2017-10-23
EA201790969A1 (ru) 2017-11-30
HK1243666A1 (en) 2018-07-20
CA2966332C (en) 2024-04-16
ES2788697T3 (es) 2020-10-22
US20220184189A1 (en) 2022-06-16
DK3215221T3 (da) 2020-05-11

Similar Documents

Publication Publication Date Title
PH12019502875A1 (en) Antibody molecules to cd73 and uses thereof
EA202091540A1 (ru) Антитела к lilrb2
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
NI201700019A (es) Anticuerpos anti tigit
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
BR112017006664A2 (pt) terapias de combinação
JOP20150048B1 (ar) جزيئات جسم مضاد لـ lag-3 واستخداماتها
CL2016002971A1 (es) Combinación.
MX2017002856A (es) Anticuerpos siglec de reaccion cruzada.
MX393818B (es) Terapias de combinación para el tratamiento de cáncer.
TR201810635T4 (tr) Anti-jagged1 antikorları ve kullanım yöntemleri.
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
MX380252B (es) Crenezumab para usarse en el tratamiento de enfermedad de alzheimer.
EA201692552A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
AR110404A1 (es) MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES FIBRÓTICAS UTILIZANDO EL INTERFERÓN-l
PH12017500426A1 (en) Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea
MX379289B (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
MX383561B (es) Composiciones y kits para usarse en el tratamiento de un sujeto con síntomas de accidente cerebrovascular o infarto agudo de miocardio (iam).
MX2017004909A (es) Composiciones de triptamina y metodos de uso.
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
WO2015134603A3 (en) Methods for treating cancer
MX380683B (es) Lisobactina para su uso en el tratamiento de la mastitis bovina.